target,target_id,target_uniprot,target_species,ligand,ligand_id,ligand_species,ligand_pubchem_cid,smiles,inchi,inchikey,type,action,action_comment,endogenous,primary_target,concentration_range,affinity_parameter,affinity_high,affinity_median,affinity_low,original_affinity_units,original_affinity_low_nm,original_affinity_median_nm,original_affinity_high_nm,original_affinity_relation,assay_description,receptor_site,ligand_context,pubmed_id OXE receptor,271,Q8TDS5,Human,5S-HPETE,2483,,5280778,CCCCC/C=C\C/C=C\C/C=C\C=C\[C@H](CCCC(=O)O)OO,"InChI=1S/C20H32O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(24-23)17-15-18-20(21)22/h6-7,9-10,12-14,16,19,23H,2-5,8,11,15,17-18H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-14+/t19-/m1/s1",JNUUNUQHXIOFDA-JGKLHWIESA-N,Agonist,Full agonist,,yes,,,pEC50,,7.0,,EC50,,100.0,,=,,,,16039985, OXE receptor,271,Q8TDS5,Human,5S-HETE,3390,,5280733,CCCCC/C=C\C/C=C\C/C=C\C=C\[C@H](CCCC(=O)O)O,"InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(21)17-15-18-20(22)23/h6-7,9-10,12-14,16,19,21H,2-5,8,11,15,17-18H2,1H3,(H,22,23)/b7-6-,10-9-,13-12-,16-14+/t19-/m1/s1",KGIJOOYOSFUGPC-JGKLHWIESA-N,Agonist,Full agonist,,yes,,,pEC50,7.2,,6.5,EC50,300.0,,60.0,=,,,,7803484|8387490|16039985, OXE receptor,271,Q8TDS5,Human,5-oxo-ETE,3391,,5283159,CCCCC/C=C\C/C=C\C/C=C\C=C\C(=O)CCCC(=O)O,"InChI=1S/C20H30O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(21)17-15-18-20(22)23/h6-7,9-10,12-14,16H,2-5,8,11,15,17-18H2,1H3,(H,22,23)/b7-6-,10-9-,13-12-,16-14+",MEASLHGILYBXFO-XTDASVJISA-N,Agonist,Full agonist,,yes,,,pEC50,8.5,,8.3,EC50,5.0,,3.1,=,,,,7797484|19450703|18292294|9829988|1326548, OXE receptor,271,Q8TDS5,Human,5-oxo-C20:3,3392,,56947094,CCCCCCCC/C=C\C/C=C\C=C/C(=O)CCCC(=O)O,"InChI=1S/C20H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(21)17-15-18-20(22)23/h9-10,12-14,16H,2-8,11,15,17-18H2,1H3,(H,22,23)/b10-9-,13-12-,16-14-",ULMVEQWNDGUUBR-IEQFDQMRSA-N,Agonist,Full agonist,,yes,,,pEC50,,8.0,,EC50,,10.0,,=,,,,18292294, OXE receptor,271,Q8TDS5,Human,[3H]5-oxo-ETE,3416,,5283159,CCCCC/C=C\C/C=C\C/C=C\C=C\C(=O)CCCC(=O)O,"InChI=1S/C20H30O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19(21)17-15-18-20(22)23/h6-7,9-10,12-14,16H,2-5,8,11,15,17-18H2,1H3,(H,22,23)/b7-6-,10-9-,13-12-,16-14+",MEASLHGILYBXFO-XTDASVJISA-N,Agonist,Agonist,,,,,pKd,,8.4,,Kd,,3.8,,=,,,,9829988, OXE receptor,271,Q8TDS5,Human,5-oxo-ODE,6164,,71751402,CCCCCCCCC/C=C\C=C\C(=O)CCCC(=O)O,"InChI=1S/C18H30O3/c1-2-3-4-5-6-7-8-9-10-11-12-14-17(19)15-13-16-18(20)21/h10-12,14H,2-9,13,15-16H2,1H3,(H,20,21)/b11-10-,14-12+",YVWMHFYOIJMUMN-HSINTONASA-N,Agonist,Full agonist,,yes,,,pEC50,,8.0,,EC50,,10.0,,=,,,,18287092, OXE receptor,271,Q8TDS5,Human,5-oxo-15-HETE,6167,,6438757,CCCCC[C@@H](/C=C/C=C\C/C=C\C=C\C(=O)CCCC(=O)O)O,"InChI=1S/C20H30O4/c1-2-3-9-13-18(21)14-10-7-5-4-6-8-11-15-19(22)16-12-17-20(23)24/h5-8,10-11,14-15,18,21H,2-4,9,12-13,16-17H2,1H3,(H,23,24)/b7-5-,8-6-,14-10+,15-11+/t18-/m0/s1",RIUDRKHGFDAKPO-WWWYWCMOSA-N,Agonist,Full agonist,,yes,,,pEC50,,7.7,,EC50,,20.0,,=,,,,7803484|8387490|7797484|8598482, OXE receptor,271,Q8TDS5,Human,5-oxo-20-HETE,6169,,73755178,OCCCCC/C=C\C/C=C\C/C=C\C=C\C(=O)CCCC(=O)O,"InChI=1S/C20H30O4/c21-18-13-11-9-7-5-3-1-2-4-6-8-10-12-15-19(22)16-14-17-20(23)24/h2-5,8,10,12,15,21H,1,6-7,9,11,13-14,16-18H2,(H,23,24)/b4-2-,5-3-,10-8-,15-12+",DTSRZRUIWKDHMR-DHYYJNSCSA-N,Agonist,Full agonist,,yes,,,pEC50,,6.5,,EC50,,340.0,,=,,,,8598482, OXE receptor,271,Q8TDS5,Human,5-oxo-12-HETE,6171,,10568747,CCCCC/C=C\C[C@@H](/C=C/C=C\C=C\C(=O)CCCC(=O)O)O,"InChI=1S/C20H30O4/c1-2-3-4-5-6-9-13-18(21)14-10-7-8-11-15-19(22)16-12-17-20(23)24/h6-11,14-15,18,21H,2-5,12-13,16-17H2,1H3,(H,23,24)/b8-7-,9-6-,14-10+,15-11+/t18-/m0/s1",MLZJFLKEKVDNAZ-XPKTZJOPSA-N,Antagonist,Antagonist,,yes,,,pIC50,,6.3,,IC50,,500.0,,=,,,,9920859, OXE receptor,271,Q8TDS5,Human,Gue1654,6173,,5066134,CSc1nc2c(s1)c1sc(nc1cc2)NC(=O)C(c1ccccc1)c1ccccc1,"InChI=1S/C23H17N3OS3/c1-28-23-25-17-13-12-16-19(20(17)30-23)29-22(24-16)26-21(27)18(14-8-4-2-5-9-14)15-10-6-3-7-11-15/h2-13,18H,1H3,(H,24,26,27)",UFOBDFMYJABXGK-UHFFFAOYSA-N,Allosteric modulator,Negative,,,,,pIC50,,6.0,,IC50,,1000.0,,~,,,,22634634, OXE receptor,271,Q8TDS5,Human,5-(6-chloro-2-hexyl-1H-indol-1-yl)-5-oxo-valeric acid,6174,,71655222,CCCCCCc1cc2c(n1C(=O)CCCC(=O)O)cc(cc2)Cl,"InChI=1S/C19H24ClNO3/c1-2-3-4-5-7-16-12-14-10-11-15(20)13-17(14)21(16)18(22)8-6-9-19(23)24/h10-13H,2-9H2,1H3,(H,23,24)",KNTPSPKZGNVRML-UHFFFAOYSA-N,Antagonist,Antagonist,,,,,pIC50,,6.4,,IC50,,400.0,,=,,,,23581530, OXE receptor,271,Q8TDS5,Human,S‐Y048,11073,,122588231,C[C@@H](CC(=O)c1c(CCCCCCc2cccc(c2)Cl)n(c2c1cc(Cl)cc2)C)CC(=O)O,"InChI=1S/C27H31Cl2NO3/c1-18(15-26(32)33)14-25(31)27-22-17-21(29)12-13-23(22)30(2)24(27)11-6-4-3-5-8-19-9-7-10-20(28)16-19/h7,9-10,12-13,16-18H,3-6,8,11,14-15H2,1-2H3,(H,32,33)/t18-/m0/s1",XGNFPJZMWOIDAH-SFHVURJKSA-N,Antagonist,Antagonist,,,,,pIC50,,10.7,,IC50,,0.02,,=,Inhibition of 5‐oxo‐ETE‐induced calcium mobilization in human neutrophils.,,,31655025,